MenQuadfi (meningococcal group A, C, W-135 and Y conjugate vaccine)
- Region
- 🇪🇺 EU
- Active substance
- meningococcal group A, C, W-135 and Y conjugate vaccine
- Company
- Sanofi Winthrop Industrie
- Status
- Authorised
- Therapeutic area
- Meningitis, Meningococcal
- CHMP opinion
- Thu 17 Sep 2020
- EU approval
- Wed 18 Nov 2020
- Application
- EMEA/H/C/005084
- ATC
- J07AH08
- Official record
- www.ema.europa.eu
Indication
MenQuadfi is indicated for active immunisation of individuals from the age of 6 weeks and older against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y. The use of this vaccine should be in accordance with available official recommendations.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Menveo Authorised · GSK Vaccines S.r.l.
Follow MenQuadfi
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.